Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114821 | 0.85 | HPGD (0.58) | RAB9ANPC1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL29980222 | 0.85 | HPGD (0.58) | RAB9ANPC1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL8737022 | 0.82 | SMN1; SMN2 (0.63) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL31280487 | 0.82 | SMN1; SMN2 (0.63) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28220200 | 0.81 | HPGD (0.55) | RAB9ANPC1SMN1; SMN2KDM4ECYP3A4 | |
| SCHEMBL3391165 | 0.81 | CTSD (0.49) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL6899659 | 0.80 | RXFP1 (0.53) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL28220927 | 0.79 | SMN1; SMN2 (0.59) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8565804 | 0.79 | HPGD (0.43) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL8559644 | 0.78 | MAPT (0.53) | KDM1AMEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2010-11-25 | — | — | US | disclosed |
| EP-2207547-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | KIRIN PHARMA KABUSHIKI KAISHA (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| WO-2009045700-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009045700-A2 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-7495104-B2 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1566379-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-08-24 | — | — | EP | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-03-03 | — | — | US | disclosed |
| US-6821987-B2 | 4-SUBSTITUTED BY AZOLYLUREIDO-PHENOXY, OR PHENYLTHIO; ANTITUMOR AGENTS; TREATING DIABETIC RETINOPATHY, CHRONIC RHEUMATISM, PSORIASIS, ATHEROSCLEROSIS, | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-23 | — | — | US | disclosed |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1447405-A1 | QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-08-18 | — | — | EP | disclosed |
| EP-1382604-A1 | QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | KIRIN BEER KABUSHIKI KAISHA (JP) | 2003-05-08 | — | — | US | disclosed |
| US-5814646-A | TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
| US-5624937-A | TREATMENT OF ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 1997-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270391-A1 | THIENOPYRIDINE DERIVATIVE, OR QUINOLINE DERIVATIVE, OR QUINAZOLINE DERIVATIVE, HAVING c-MET AUTOPHOSPHORYLATION INHIBITING POTENCY | MET, ABL1, RET | KDM1A 2616/4885RAB9A 2323/4885MEN1 638/4885 |
| US-20050049264-A1 | Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors | FGFR1, FGFR2, FGFR3 | KDM1A 2356/4885RAB9A 1262/4885MEN1 3194/4885 |
| US-20100298343-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | KDM1A 3241/4885RAB9A 3493/4885MEN1 4629/4885 |
| US-20040229876-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | KDM1A 703/4885RAB9A 229/4885MEN1 858/4885 |
| US-20030087907-A1 | Quinoline derivatives and quinazoline derivatives having azolyl group | NQO2, H1-5, NRAS | KDM1A 703/4885RAB9A 229/4885MEN1 858/4885 |
| US-20080207617-A1 | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same | FLT3, TYRO3, ABL1 | KDM1A 1816/4885RAB9A 721/4885MEN1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.